22 results about "Antibody induction" patented technology

Disclosed herein are antibodies that specifically bind to Gal3 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting T cell or Natural Killer cell proliferation with an antibody that specifically binds to Gal3. Also disclosed herein are methods and compositions of reducing fibrosis or propensity thereof in a tissue with antibodies that specifically bind to Gal3. In some cases, the anti-Gal3 antibody also disrupts the interaction between Gal3 and TIM-3.

The present invention is directed to multispecific molecules that bind immunoglobulin and a recycling target. Binding immunoglobulin and a recycling target results in degradation of immunoglobulin and in certain embodiments recycling of the multispecific molecule. The multispecific molecules of the present invention are thought to be useful in the treatment of autoantibody-induced diseases.

To provide the use of a CBR1 agonist as an adjuvant and an adjuvant composition.SOLUTION: A compound represented by formula (1): Wherein R represents a cyclopropyl group or a 2-chloroethyl group. The antibody induction-promoting agent contains a compound represented by general formula (I) as an active ingredient.SELECTED DRAWING: None

The present invention solves the problem of providing a novel therapeutic agent for treating patients suffering from anti-NMDAR encephalitis. Patients suffering from anti-NMDAR encephalitis have pathogenic anti-human NR1 antibodies, which induce the internalization of NMDAR on the cell surface. As a result, the NMDAR function in the brains of such patients is weakened. The inventors of the present invention have found that the single-arm anti-human NR1 antibody according to the present invention competitively binds to NR1 with the pathogenic anti-human NR1 antibody and inhibits the internalization of NMDAR by the pathogenic anti-human NR1 antibody, thereby showing a therapeutic effect against anti-NMDAR encephalitis. Accordingly, the present invention provides a single-arm anti-human NR1 antibody, a polynucleotide encoding the antibody, an expression vector containing the polynucleotide, a host cell transformed by the expression vector, a method for producing the antibody, a pharmaceutical composition containing the antibody, the use of the antibody in the manufacture of the pharmaceutical composition, and a method for treating anti-NMDAR encephalitis using the antibody.

In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelopes with optimized V2 loop for antibody induction.

The invention belongs to the field of medicinal chemistry and pharmacology, and relates to application of a novel glycolipid TLR2 agonist 13-C in preparation of vaccine adjuvants and anti-tumor treatment. The compound is excellent in human TLR2 agonist activity, EC50 reaches 2.2 nM, and the compound is simple in structure, easy to prepare and excellent in solubility and has industrial application potential. In a B16-OVA tumor model, the antibody induction capacity of the compound is superior to that of a positive control drug Diprovocim, and the anti-tumor activity of the compound is more remarkable; in addition, PD-L1 expression of tumor tissue can be effectively down-regulated, and a synergistic anti-tumor effect is generated with a PD-L1 monoclonal antibody Atezolizumab. Besides, 13-C and a vaccine adjuvant QS-21 are combined for use, so that a synergistic enhancement effect is achieved, the antibody titer induced by a vaccine can be remarkably improved, antibody subtypes are enriched, meanwhile, cellular immunity and humoral immunity response of an organism are stimulated, and the effect of dual immune activation is achieved.

Provided are coronavirus spike protein variants for use as antigens for vaccines for coronavirus infections.　The present invention provides coronavirus spike protein variants comprising (a) a receptor binding domain (RBD) formed from the amino acid sequence set forth in SEQ ID NO: 1, (b) an RBD formed from an amino acid sequence in which one to several amino acids have been substituted, deleted, inserted, or added in the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to RBD formed from the amino acid sequence set forth in SEQ ID NO: 1, or (c) an RBD formed from an amino acid sequence having at least 90% sequence identity with the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to RBD formed from the amino acid sequence set forth in SEQ ID NO: 1.

In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelopes with optimized V2 loop for antibody induction.

The application discloses an ASFV dominant antigen epitope tandem recombinant protein, and an amino acid sequence of the ASFV dominant antigen epitope tandem recombinant protein is shown as SEQ ID NO:1, and belongs to the field of biology. The P54 and B602L proteins of the high immunogenicity region of the screened ASFV dominant antigen epitope are tandemly expressed according to the antibody induction efficiency in a pig group to obtain the recombinant protein. An ASFV indirect ELISA detection method is established by taking the recombinant protein as an antigen. The method has high accuracy, good specificity and high sensitivity, and has a large application prospect in the prevention and control of the ASF disease.

A structurally intact red blood cell membrane, a preparation method therefor and the use thereof. Defining components of a release solution to lyse red blood cells allows for mild conditions, and can release protein components such as hemoglobin inside the red blood cells, remove cell properties thereof, keep the integrity of the cytoskeleton thereof and the activity of surface antigens of the membrane, and retain key blood group antigens on the surface of the red blood cell membrane while keeping the complete structure of the red blood cell membrane, thus reducing the problem of antigenicity reduction caused by fragmentation of the red blood cell membrane. After the red blood cells are lysed, nanoparticles are coupled to the surface of the red blood cell membrane, thus visualizing the agglutination reaction of the red blood cell membrane under the induction of antibodies. Using a fixed procedure to preserve engineered red blood cell biomembranes can effectively avoid damage to the engineered red blood cell biomembrane caused by ice crystals, ensure that the antigenicity of the membranes is not affected, allow for long-term preservation at room temperature, and prolong the shelf life to two years or more.

In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelopes with optimized sequences for antibody induction. In some embodiments, the invention provides mRNA sequences of said HIV-1 immunogens.

The present invention relates to multispecific molecules that bind to immunoglobulins and recirculating targets. Binding the immunoglobulin and the recirculation target causes the immunoglobulin to degrade, and in certain embodiments, the multispecific molecule to recirculate. The multispecific molecules of the present invention are believed to be useful in the treatment of autoantibody-induced diseases.

The invention discloses a riemerella anatipestifer glucosamine oligosaccharide protein conjugate as well as a preparation method and application thereof, the glucosamine oligosaccharide protein conjugate is formed by connecting glucosamine oligosaccharide and carrier protein through a linking group, and the structural general formula of the glucosamine oligosaccharide protein conjugate is as shown in formula (III). The glucosamine oligoglycoprotein conjugate with a clear structure is prepared by utilizing a chemical synthesis method. An enzyme-linked immunosorbent assay experiment result shows that serum of a positive immune mouse and glucosamine oligosaccharides with different chain lengths have different recognition effects, and the glucosamine oligoglycoprotein conjugate can excite an antigen-specific IgG antibody with very high titer and an IgM antibody with high titer, induce a strong T-cell dependent protective immunoreaction, and can be used for preparing the immunosorbent assay kit. After immunization, serum can be obviously combined with inactivated riemerella anatipestifer. Therefore, the glucosamine oligosaccharide protein conjugate provided by the invention has relatively high application value in preparation of vaccines for resisting riemerella anatipestifer infection and drug development. In addition, the preparation steps are simple, and the yield is high.

The present invention addresses the problem of providing a novel therapeutic agent for treating patients with anti NMDAR encephalitis. Patients with an anti NMDAR encephalitis have a pathogenic anti-human NR1 antibody that induces internalization of NMDAR on cell surface. As a result, NMDAR function is weakened in the patients' brain. The present inventors found that the one-armed anti-human NR1 antibody according to the present invention binds to NR1 competitively with the pathogenic anti-human NR1 antibody and inhibits the internalization of NMDAR by the pathogenic anti-human NR1 antibody to thereby exhibit therapeutic effect on anti NMDAR encephalitis. Accordingly, the present invention provides the a one-armed anti-human NR1 antibody, a polynucleotide encoding the antibody, an expression vector containing the polynucleotide, a host cell transformed by the expression vector, a method for producing the antibody, a pharmaceutical composition comprising the antibody, a use of the antibody in the manufacture of the pharmaceutical composition, and a method for treating anti NMDAR encephalitis using the antibody.

The present disclosure relates to chimeric antigen receptors (CARs) comprising an extracellular accessory domain through which T-cells expressing the CARs can be activated in an antigen-independent fashion. In particular, the extracellular accessory domain of the CARs of the present disclosure is an antibody-inducible domain that is bindable by an antibody or a polypeptide comprising an antigen-binding fragment thereof. In this way, T-cells expressing the CARs are activatable by binding of the antibody to the antibody-inducible domain.

This document provides antibodies against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) short, and more particularly to humanized TRAILshort antibodies that can neutralize TRAILshort. For example, materials and methods for using one or more humanized TRAILshort antibodies to induce apoptosis (e.g., via TRAIL mediated cell death, natural killer (NK) cytotoxicity, and / or CD8+ T cell killing) are provided.

In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelopes with optimized V2 loop for antibody induction.

The present invention relates to multispecific molecules that bind to immunoglobulins and recycling targets. Binding of the immunoglobulin to a recycling target results in degradation of the immunoglobulin and, in certain embodiments, recycling of the multispecific molecule. The multispecific molecules of the invention are believed to be useful in the treatment of autoantibody-induced diseases.

The present invention belongs to the technical fields of cell engineering and biochemical detection, and particularly relates to a structurally complete red blood cell membrane, a preparation method thereof, and an application thereof. The present invention lyses red blood cells by defining the components of a release solution, with mild conditions, which can release protein components such as hemoglobin inside the red blood cells, remove their cell attributes, retain the integrity of their internal skeleton structure and the activity of membrane surface antigens, and while maintaining the complete structure of the red blood cell membrane, retain the key blood group antigens on its surface, avoiding the problem of reduced antigenicity caused by fragmentation of the red blood cell membrane. After lysing the red blood cells, nanoparticles are conjugated to the surface of the red blood cell membrane, enabling the agglutination reaction of the red blood cell membrane induced by antibodies to be visualized. Using a fixed procedure to preserve the engineered red blood cell biomembrane can effectively avoid damage to the engineered red blood cell biomembrane by ice crystals, ensure that the antigenicity of the membrane is not affected, and can be stored at room temperature for a long time, with the shelf life extended to two years or more.

The present disclosure relates to chimeric antigen receptors (CARs) comprising an extracellular accessory domain through which T-cells expressing the CARs can be activated in an antigen-independent fashion. In particular, the extracellular accessory domain of the CARs of the present disclosure is an antibody-inducible domain that is bindable by an antibody or a polypeptide comprising an antigen-binding fragment thereof. In this way, T-cells expressing the CARs are activatable by binding of the antibody to the antibody-inducible domain.

In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelopes with optimized sequences for antibody induction.

The present invention relates to the field of biomedical technology, and discloses anti-tumor small molecule compounds targeting FGL2, including any one of the small molecule compounds C16H17N3O2 and C14H16N2O2S2; and also discloses the application thereof. The present invention has discovered a small molecule compound C16H17N3O2 that can specifically bind to FGL2. 16 H 17 N3O2 and C 14 H 16 N2O2S2, the above two small molecule compounds can insert into the pocket of the fibrinogen-related domain composed of 233 amino acids at the C-terminus of the FGL2 protein and bind tightly; the above two small molecule compounds interfere with the binding of FGL2 to its receptor FcγRIIB, thereby promoting the proliferation and differentiation of T cells induced by anti-CD3 antibodies + anti-CD28 antibodies, thereby promoting the function of T cells and interfering with the activation of myeloid-derived immunosuppressive cells (MDSCs), thereby inducing tumor clearance, and can be used in tumor diseases with high expression of FGL2, such as liver cancer, severe hepatitis and other related diseases.